SCHEMBL420516

SCHEMBL420516

COc1cccc(-c2oc(C(=O)N3CNC(=O)C3)cc2-c2cccc(Cl)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.45
ABCB1 P08183 1/20 0.40
TP53 P04637 1/20 0.39
GAPDH P04406 1/20 0.39
GPR35 Q9HC97 2/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PDE4B Q07343 1/20 0.38
WNK1 Q9H4A3 1/20 0.38
PDE2A O00408 1/20 0.37
EGFR P00533 4/20 0.37
HSD17B3 P37058 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MGLL Q99685 1/20 0.36
CCKAR P32238 1/20 0.36
DGAT2 Q96PD7 1/20 0.36
MMP2 P08253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102797 0.91 PDE4B (0.41) TP53MAPTSMN1; SMN2PDE4B
SCHEMBL417917 0.91 MAOB (0.44) MAOBABCB1TP53GAPDHGPR35
SCHEMBL2510578 0.86 PDE4B (0.38) GPR35MAPTSMN1; SMN2PDE4BMEN1
SCHEMBL417480 0.84 PDE4B (0.38) TP53MAPTSMN1; SMN2PDE4BMEN1
SCHEMBL418259 0.83 PDE4B (0.37) TP53MAPTSMN1; SMN2PDE4BMEN1
SCHEMBL419600 0.81 PDE4B (0.44) TP53MAPTSMN1; SMN2PDE4BMEN1
SCHEMBL415848 0.80 KDM4E (0.36) MAPTHPGDPDE4B
SCHEMBL421433 0.80 PDE4B (0.41) TP53MAPTHPGDSMN1; SMN2PDE4B
SCHEMBL419496 0.80 PDE4B (0.41) TP53MAPTSMN1; SMN2PDE4BMEN1
SCHEMBL421535 0.79 PDE4B (0.41) MAOBSMN1; SMN2PDE4BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 EP disclosed
EP-2376479-B1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO KG (DE) 2016-03-02 EP disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
EP-2376479-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AiCuris GmbH & Co. KG (DE) 2011-10-19 EP disclosed
WO-2010075957-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed
WO-2010075957-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AADAC, DDC, TPMT MAOB 272/4885ABCB1 216/4885TP53 2513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.